Clinical Trial Update: Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing elagolix to subcutaneous depot medroxyprogesterone acetate for endometriosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• Depot-medroxyprogesterone acetate (DMPA) (medroxyprogesterone acetate)
• Elagolix (elagolix)

Snippet

Sponsor: AbbVie | Conditions: Endometriosis | Phase 2 | Status: COMPLETED | Results posted: 2018-10-12